Meeting
2014 ASCO Annual Meeting
Does increasing the daily tamoxifen dose in patients with diminished CYP2D6 activity increase toxicity?
Authors
Daniel Louis Hertz
University of Michigan, Ann Arbor, MI
Daniel Louis Hertz , Anna C. Snavely , James P Evans , Joseph G Ibrahim , Steven M. Anderson , Kenneth J Friedman , Karen E Weck , Peter Rubin , Oludamilola A. Olajide , Susan G. Moore , Rachel Elizabeth Raab , Daniel R. Carrizosa , Steven William Corso , Garry Schwartz , Jeffrey M. Peppercorn , Mark Graham , Sean Thomas Canale , Howard L. McLeod , Lisa A. Carey , William Johnson Irvin Jr.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00764322
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 561)
DOI
10.1200/jco.2014.32.15_suppl.561
Abstract #
561
Poster Bd #
25
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
First Author: Gerardus Hussaarts
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2016 ASCO Annual Meeting
Comparison of endoxifen levels between male and female breast cancer patients treated with tamoxifen.
First Author: John Gordon Lenehan
Poster
2013 ASCO Annual Meeting
Effect of PK-guided tamoxifen dose escalation on endoxifen serum concentrations in CYP2D6 intermediate and poor metabolizers.
First Author: Frans Opdam